Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?

机译：佐剂表皮生长因子受体酪氨酸激酶抑制剂：我们实际准备好了吗？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Translational Lung Cancer Research
作者
Fabrizio Tabbò; Maria Lucia Reale; Silvia Novello;
展开▼
作者单位

展开▼
年(卷),期 2020(9),5
年度 2020
页码 1724–1727
总页数 4
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor? [J] . Banno Eri, Togashi Yosuke, Nakamura Yu, Cancer science. . 2016,第8期

机译：对不常见的表皮生长因子受体突变L861Q和S768I的各种表皮生长因子受体-酪氨酸激酶抑制剂的敏感性：最佳的表皮生长因子受体-酪氨酸激酶抑制剂是什么？
2. Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor? [J] . Banno Eri, Togashi Yosuke, Nakamura Yu, Cancer science. . 2016,第8期

机译：对各种表皮生长因子受体酪氨酸激酶抑制剂的罕见表皮生长因子受体突变L861Q和S768I的敏感性：最佳的表皮生长因子受体酪氨酸激酶抑制剂是什么？
3. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor? [J] . Banno Eri, Togashi Yosuke, Nakamura Yu, Cancer science. . 2016,第8期

机译：对各种表皮生长因子受体 - 酪氨酸激酶抑制剂的敏感性罕见表皮生长因子受体突变L861Q和S768i：什么是最佳表皮生长因子受体 - 酪氨酸激酶抑制剂是什么？
4. QSAR Study of Quinazoline Derivatives as Inhibitor of Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK) [C] . La Ode Aman, Widisusanti Abdulkadir, Julitha Geybie Rembet, International Conference on Computation for Science and Technology . 2015

机译：喹唑啉衍生物作为表皮生长因子受体 - 酪氨酸激酶（EGFR-TK）抑制剂的QSAR研究
5. Unanticipated Effects of Tyrosine Kinase Inhibitors on Vitamin D Receptor Expression and Gene Regulation In Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer. [D] . Timberlake, Alexandra F. 2017

机译：酪氨酸激酶抑制剂对表皮生长因子受体突变的非小细胞肺癌中维生素D受体表达和基因调控的意外影响。
6. Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor? [O] . Eri Banno, Yosuke Togashi, Yu Nakamura, 2016

机译：对各种表皮生长因子受体酪氨酸激酶抑制剂的罕见表皮生长因子受体突变L861Q和S768I的敏感性：最佳的表皮生长因子受体酪氨酸激酶抑制剂是什么？
7. >Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [O] . Wen Gao, Jing He, Shi-Dai Jin, 2019

机译：>初始表皮生长因子受体酪氨酸激酶抑制剂治疗和EGFR外显子抑制剂的抗血液抗性抗血液肺癌患者T790M突变抗性抗性后，抗抗血疱剂患者的抗性，抗抗血管生长因子受体酪氨酸激酶抑制剂

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?

著录项

相似文献

相关主题

期刊订阅